Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

CD64 May Be an RA-Specific Biomarker

Lara C. Pullen, PhD  |  November 2, 2015

The investigators then evaluated soluble forms of CD89, CD64 and CD16A to identify which of these receptors might have an active role in treatment response. They found elevated sCD64 was specific for RA and was not found in a reference group of patients with active psoriatic arthritis.

“With this study, we want to draw the attention to CD64 as an important player in early autoantibody positive RA,” write the authors in the discussion. “In our analyses, no other membrane-bound FcγRs were found significantly modified, and sCD64 was elevated only in RA plasma. The early naive RA monocytes were characterized by up-regulation of CD64 and membrane bound IgG.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Matt P, Lindqvist U, Kleinau S. Elevated membrane and soluble CD64: A novel marker reflecting altered FcγR function and disease in early rheumatoid arthritis that can be regulated by anti-rheumatic treatment. PLoS One. 2015 Sep 25;10(9):e0137474. doi: 10.1371/journal.pone.0137474. eCollection 2015.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:antirheumatic therapyBiomarkersRheumatoid Arthritis (RA)

Related Articles
    IgG4-Related Kidney Disease: Diagnostics, Manifestations, & More

    IgG4-Related Kidney Disease: Diagnostics, Manifestations & More

    May 17, 2018

    Immunoglobin G4-related disease (IgG4-RD) is a rare fibro-inflammatory disease of unknown etiology that has been recently recognized. It can cause fibro-inflammatory masses in almost every organ of the body and is associated with dense lymphoplasmacytic infiltration of IgG4-postitive plasma cells, storiform fibrosis and elevated levels of serum IgG4.1 IgG4-RD is a systemic disease that may…

    The Mystery of IVIg

    March 8, 2012

    Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.

    Doest Rheumatoid Arthritis Take a Toll?

    November 15, 2013

    Exploring the Toll background

    A&R Abstracts – T CELLS

    August 1, 2011

    For Further Reading

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences